Adamis Pharmaceuticals has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Drug Delivery Systems‘ Taper Dry Powder Inhaler (DPI) technology, which is under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As a part of the agreement, Adamis will obtain worldwide rights to use this platform technology in all indications in the dry powder inhalation field. The unique design uses proprietary 3M technology...